Organisation
Laboratory of Molecullar and Cellular Therapy
Research Group
The focus of the Laboratory for Molecular and Cellular Therapy (LMCT) is directed towards the application of basic immunological knowledge and molecular biotechnology for the understanding, diagnosis and treatment of human diseases, including cancer, infectious disease and brain disease.
Current researchers
1 - 10 of 32 results
- Jonathan Bastos (Responsible)
- Sanne Bevers (Responsible)
- Hannelore Ceuppens (Responsible)
- Yannick De Vlaeminck (Responsible)
- Q Lecocq (Responsible)
- Fien Meeus (Responsible)
- Dorien Autaers (Member)
- Robin Maximilian Awad (Member)
- Thomas Benoot (Member)
- Karine Breckpot (Member)
Projects
1 - 10 of 13
- eveloping microglia replacement therapy to treat progranulinassociated frontotemporal dementiaFrom1 Nov 2022 → TodayFunding: FWO fellowships
- GEAR: Integrating a multimodal approach to address current challenges in immunotherapy (INTEGRAL)From1 Jan 2020 → TodayFunding: IOF - technology validation in real environment, IOF - mandates
- GEAR: Brussels Liver Research to Valorisation Alliance (B-Liver): Valorisation of VUB’s liver cell biology and toxicology expertise via a consortium focused on liver therapeutics, patient and consumer safety.From1 Jan 2020 → TodayFunding: IOF - technology concept exploration, IOF - mandates
- Combining targeted radionuclide therapy and cancer immunotherapy to advance precision medicine through innovation.From1 Nov 2019 → 31 Oct 2021Funding: FWO fellowships
- Eccentric: Enhancing the function of Cancer Countering Effector cells using Nanobodies Targeting Regulatory Immune CheckpointsFrom1 Nov 2019 → 31 Oct 2021Funding: FWO fellowships
- A randomized phase II clinical trial in NSCLC combining SBRT and I.V. anti-PD-1 with or without I.T. anti-CTLA-4/anti-PD-L1 plus CD1c+ myDCFrom1 Oct 2019 → TodayFunding: FWO Applied Biomedical Research (TBM)
- Modulating epigenetic mechanisms to enhance cancer immunotherapy.From1 Oct 2018 → 30 Sep 2022Funding: FWO fellowships
- Inhibition of system xc-: tackling pancreatic cancer from different anglesFrom1 Oct 2018 → 30 Sep 2022Funding: FWO fellowships
- Target and explore the ‘X factor’ of the lung tumor microenvironment.From1 Jan 2018 → 31 Dec 2018Funding: FWO research grant KAN
- Strategic Research Programme: Cancer Cell Targeting in Myeloma and Melanoma (MyMe)From1 Nov 2017 → TodayFunding: University - Project driven research
Publications
1 - 10 of 369
- Image-based point spread function implementation in a fully 3D OSEM reconstruction algorithm for PET.(2010)
Authors: E Rapisarda, V Bettinardi, Kris Thielemans, Mc Gilardi
Pages: 4131-4151 - Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA(2008)
Authors: Aude Bonehill, Sandra Tuyaerts, An Van Nuffel, Carlo Heirman, Tomas J Bos, Karel Fostier, Bart Neyns, Kris Thielemans
Pages: 1170-1180 - Complete Cytologic Remission of V600E BRAF-Mutant Melanoma-Associated Leptomeningeal Carcinomatosis Upon Treatment With Dabrafenib(2015)
Authors: Sofie Wilgenhof, Bart Neyns
Pages: 109-111 - Therapeutic Vaccination With Autologous mRNA Electroporated Dendritic Cells (DC) in Patients With Advanced Melanoma(2010)
Authors: Sofie Wilgenhof, An Van Nuffel, Daphné Benteyn, Jurgen Corthals, Carlo Heirman, L. Pierret, Arlette De Coninck, Aude Bonehill, Kris Thielemans, Bart Neyns
Pages: 880-881 - Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis(2017)
Authors: Delphine Degré, Thomas Sersté, Luc Lasser, Jean Delwaide, Peter Starkel, Wim Laleman, Philippe Langlet, Hendrik Reynaert, Stefan Bourgeois, Thomas Vanwolleghem, et al.
- Choose your models wisely: How different murine bone marrow-derived dendritic cell protocols influence the success of nanoparticulate vaccines in vitro(2014)
Authors: Heleen Dewitte, R. Verbeke, Karine Breckpot, R.e. Vandenbroucke, C. Libert, Sc. De Smedt, I. Lentacker
Pages: 138-146 - The Belgian Association for Study of the Liver Guidance Document on the Management of Adult and Paediatric Non-Alcoholic Fatty Liver Disease(2018)
Authors: S. Francque, N Lanthier, L Verbeke, Hendrik Reynaert, Christophe Van Steenkiste, L Vonghia, W J Kwanten, J Weyler, Eric Trépo, D. Cassiman, et al.
Pages: 55-81 - Assessing T-cell responses in anticancer immunotherapy: Dendritic cells or myeloid-derived suppressor cells?(2013)
Authors: D. Escors, T. Liechtenstein, N. Perez-Janices, J. Schwarze, Inès Dufait, C Goyvaerts, A. Lanna, F. Arce, I. Blanco-Luquin, G. Kochan, et al.
- A personalized view on cancer immunotherapy.(2014)
Authors: L. Wayteck, Karine Breckpot, J. Demeester, Sc. De Smedt, K. Raemdonck
Pages: 113-125 - Somatostatin as Inflow Modulator in Liver-transplant Recipients With Severe Portal Hypertension(2019)
Authors: Roberto Ivan Troisi, Aude Vanlander, Mariano Cesare Giglio, Jurgen Van Limmen, Luigia Scudeller, Bjorn Heyse, Luc De Baerdemaeker, Alexander Croo, Dirk Voet, Marleen Praet, et al.
Pages: 1025-1033